Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Clinical Trial
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses
Ocean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung...
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company...
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
Investigational immunotherapy, VTP-300, is being evaluated as part of a potential functional cure regimen for chronic Hepatitis B.Interim data update...
Spago Nanomedical in New Phase with Full Focus on the Tumorad Program
LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB...
AlzeCure’s Abstract on ACD856’s Anti-inflammatory Effects to be Presented at a Leading Alzheimer’s Conference
STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
ATPC and FORMEDIC Technologies Announce Strategic Collaboration to Launch LEGA, a Revolutionary Respiratory Care Device
Innovative Collaboration Brings Advanced Respiratory Solutions to a Global Market KUALA LUMPUR, MALAYSIA / ACCESSWIRE / September 30, 2024 /...
Introducing Perceptive: A New Name for the Global Leader in Discovery, eClinical, and Imaging Services and Solutions
Calyx and Invicro rebrand, usher in a new era of leadership and support to the biopharmaceutical community NOTTINGHAM, England, Sept. 30,...
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the...
National Organization for Rare Disorders (NORD) Announces $85,000 in Grant Funding for Amyloidosis and Levy-Yeboa Syndrome
QUINCY, Mass., Sept. 30, 2024 /PRNewswire/ -- Today, the National Organization for Rare Disorders (NORD®) announced two new requests for proposal...
Piramal Pharma Solutions Announces $80M Expansion Plan for Sterile Injectables Facility in Lexington, Kentucky
$80M investment plan will add commercial scale sterile injectables capabilities Expansion will significantly increase production capacity and operational efficiency Lexington facility...
Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker...
HeartX Cardiovascular Accelerator Announces Four Startup Companies Selected for the 2024 Program
BENTONVILLE, Ark., Sept. 30, 2024 /PRNewswire/ -- HeartX, powered by HealthTech Arkansas and MedAxiom — along with numerous leading cardiology practices...
MeMed BV Test Demonstrates Antibiotic Overuse Reduction in First US Interventional Trial
—First Multi-Center Randomized Controlled Clinical Trial in the US to Show MeMed BV's Impact on Reducing Unnecessary Antibiotics, Supporting Clinical...
Emmes Group recognized as a top EDC platform by Everest Group
Emmes Group named a 'Major Contender' in the Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix® Assessment 2024 from...
NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp....
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the...
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial – Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has...
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Provides interested parties...
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Academic group to receive a total of $22 million for the trialLA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) --...